domingo, 19 de abril de 2026

Humanity first, not country first The Lancet Regional Health – Europe + +... ++ +...

The effectiveness of psychosocial interventions for self-harm in males compared to females: a systematic review and meta-analysis Oliver Matias Oliver.Matias@citystgeorges.ac.uk ∙ Alexandra E. Bakou ∙ Kirsten Barnicot ∙ Rose McCabe https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(26)00018-9/fulltext?dgcid=hubspot_update_feature_updatealerts_lanepe&utm_campaign=update-lanepe&utm_medium=email&_hsenc=p2ANqtz-_6QghD46vbVyE0L1AwSpldCO9iYyG-U0C7iKQk0oYrtVqrUuzCAC1_93ylRZN_kH_fimm7B5n0xzl2HiMz8tgC4ifdRw&_hsmi=413587672&utm_content=413506161&utm_source=hs_email Cutting-edge systemic cancer therapies Executive summary Systemic cancer therapies are undergoing rapid transformation, redefining precision and durability in oncologic treatment. This Series examines advances across antibody–drug conjugates, cell therapies, multispecific antibodies, and immunologically driven strategies such as oncolytic viruses and cancer vaccines. It highlights how innovations in molecular design, conjugation technologies, and antibody engineering are expanding therapeutic potential while introducing challenges related to toxicity, cost, and access. The Series also explores the growing role of engineered cell therapies in haematological malignancies and solid tumours, emphasising Europe’s scientific leadership alongside regulatory and manufacturing barriers. Advances in immune engagement underscore a shift toward more precise and durable antitumour responses, while reinforcing the need for biomarker-guided patient selection and system-level solutions to translate innovation into equitable clinical benefit. https://www.thelancet.com/series-do/cancer-therapies?dgcid=hubspot_update_feature_lanepecancertherapies26&utm_campaign=update-lanepe&utm_medium=email&_hsenc=p2ANqtz-9Iv30TOsv86ubzEPvvi7y09sDdaNoJxYby5gKpAJq_uAuz1hIvQpGLf2MgjAH0enHrK161StJw5_-if2okpprLT1f70g&_hsmi=413587672&utm_content=413506161&utm_source=hs_email European medicines agency approvals of new medicines in January and February 2026 Bruno Sepodesa,b ∙ Juan Garcia Burgosc ∙ Steffen Thirstrup https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(26)00069-4/fulltext?dgcid=hubspot_update_feature_updatealerts_lanepe&utm_campaign=update-lanepe&utm_medium=email&_hsenc=p2ANqtz-9THJdPjb1atX04h2d9CGSxtNbidbKL6AHPyZO5Y7ErBrwLtOtjg9HCH8GafIDDrff_OPsoB5FAJ1yYWiF6U4RKGcIKkg&_hsmi=413587672&utm_content=413506161&utm_source=hs_email Humanity first, not country first The Lancet Regional Health – Europe https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(26)00076-1/fulltext?dgcid=hubspot_update_feature_updatealerts_lanepe&utm_campaign=update-lanepe&utm_medium=email&_hsenc=p2ANqtz--v2vIxd72bJVaEkaNOXJ2X-9-cCUsdGPGZ3hn_zSKQL11EW4Lj7f0AxQnBKQ9qjNNIutT1d9ZcxapW9d9H0Zl_YrbV7A&_hsmi=413587672&utm_content=413506161&utm_source=hs_email Apr 2026 Volume 63 https://www.thelancet.com/journals/lanepe/issue/vol63nonull/PIIS2666-7762(25)X0014-4

No hay comentarios:

Publicar un comentario